Covered recipient · General Payments record
MARSHALL PATRICK STAGG
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$4,856.11
154 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $3,622.15 | 138 |
| Long term medical supply or device loan | $999.96 | 12 |
| Education | $234.00 | 4 |
By paying entity
PY2024 · entire year · sorted by reported total
Page 3 of 4; records 101–150 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MARSHALL PATRICK STAGG
NPI 1841281573 · CMS profile ID 356363
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
BATON ROUGE, LA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 4; records 101–150 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1841281573?year=2024&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MARSHALL PATRICK STAGG, NPI 1841281573, CMS profile ID 356363. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1841281573?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). MARSHALL PATRICK STAGG, NPI 1841281573, CMS profile ID 356363. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1841281573?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- MARSHALL PATRICK STAGG, NPI 1841281573, CMS profile ID 356363, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1841281573?year=2024&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
154 matching records · $4,856.11 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 154.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. | $24.37 | 04/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133801976 | CMS |
| Tempus AI, Inc | $6.34 | 04/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150175074 | CMS |
| Novartis Pharmaceuticals Corporation | $83.33 | 04/18/2024 | Long term medical supply or device loan | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087270679 | CMS |
| Regeneron Healthcare Solutions, Inc. | $25.66 | 04/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114192676 | CMS |
| E.R. Squibb & Sons, L.L.C. | $23.05 | 04/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101376154 | CMS |
| Novartis Pharmaceuticals Corporation | $23.20 | 04/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087270613 | CMS |
| Incyte Corporation | $22.33 | 04/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141213370 | CMS |
| AstraZeneca Pharmaceuticals LP | $20.81 | 04/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105508294 | CMS |
| Amgen Inc. | $77.10 | 04/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117691422 | CMS |
| Ipsen Biopharmaceuticals, Inc | $58.50 | 04/03/2024 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1091958024 | CMS |
| Ipsen Biopharmaceuticals, Inc | $58.50 | 04/03/2024 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1091958028 | CMS |
| Ipsen Biopharmaceuticals, Inc | $58.50 | 04/03/2024 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1091958032 | CMS |
| Ipsen Biopharmaceuticals, Inc | $58.50 | 04/03/2024 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1091958035 | CMS |
| Janssen Biotech, Inc. | $16.28 | 04/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078666755 | CMS |
| Eisai Inc. | $20.75 | 04/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110764031 | CMS |
| Merck Sharp & Dohme LLC | $32.11 | 03/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141625677 | CMS |
| Regeneron Pharmaceuticals, Inc. | $109.83 | 03/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114405387 | CMS |
| Genentech USA, Inc. | $18.19 | 03/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133063648 | CMS |
| Daiichi Sankyo Inc. | $26.27 | 03/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1089486314 | CMS |
| Gilead Sciences, Inc. | $19.70 | 03/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133801974 | CMS |
| Exelixis Inc. | $19.66 | 03/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1138561610 | CMS |
| Novartis Pharmaceuticals Corporation | $83.33 | 03/15/2024 | Long term medical supply or device loan | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087270677 | CMS |
| AstraZeneca Pharmaceuticals LP | $20.39 | 03/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105813565 | CMS |
| Ipsen Biopharmaceuticals, Inc | $12.40 | 03/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1091958019 | CMS |
| EMD Serono, Inc. | $16.94 | 03/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1120227376 | CMS |
| PFIZER INC. | $22.98 | 03/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131288557 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $28.18 | 03/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086174862 | CMS |
| Novartis Pharmaceuticals Corporation | $18.98 | 03/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087270611 | CMS |
| Novartis Pharmaceuticals Corporation | $9.73 | 03/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087270607 | CMS |
| BeiGene USA, Inc. | $19.12 | 02/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1120864160 | CMS |
| Celgene Corporation | $22.57 | 02/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101122460 | CMS |
| Aveo Pharmaceuticals, Inc. | $23.20 | 02/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143481989 | CMS |
| AstraZeneca Pharmaceuticals LP | $25.84 | 02/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105481889 | CMS |
| Alexion Pharmaceuticals, Inc. | $15.96 | 02/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1093896447 | CMS |
| GENZYME CORPORATION | $16.11 | 02/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139967305 | CMS |
| Novartis Pharmaceuticals Corporation | $83.33 | 02/16/2024 | Long term medical supply or device loan | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087270675 | CMS |
| Tempus AI, Inc | $27.66 | 02/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150175072 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $28.11 | 02/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1144968274 | CMS |
| AstraZeneca Pharmaceuticals LP | $25.22 | 02/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105490853 | CMS |
| Novartis Pharmaceuticals Corporation | $22.41 | 02/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087270605 | CMS |
| PFIZER INC. | $14.61 | 02/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131075639 | CMS |
| Agios Pharmaceuticals, Inc. | $74.67 | 02/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1149646436 | CMS |
| Incyte Corporation | $15.59 | 02/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141179324 | CMS |
| ADC Therapeutics America, Inc. | $22.04 | 01/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1121190929 | CMS |
| Tempus AI, Inc | $15.56 | 01/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150175070 | CMS |
| Merck Sharp & Dohme LLC | $16.32 | 01/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141625681 | CMS |
| Celgene Corporation | $22.63 | 01/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101122456 | CMS |
| Merck Sharp & Dohme LLC | $29.38 | 01/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141918918 | CMS |
| Novartis Pharmaceuticals Corporation | $83.33 | 01/18/2024 | Long term medical supply or device loan | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087270673 | CMS |
| Incyte Corporation | $19.58 | 01/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141212567 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $490,331.12 | 32 |
| PY2024 | Principal investigator | $759,128.66 | 38 |
| PY2023 | Principal investigator | $301,996.27 | 18 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
32 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $72.00 | 12/31/2025 | Covered Recipient Teaching Hospital OUR LADY OF THE LAKE RMC | A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab Monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) when Administered in the Outpatient Setting | No dispute reported | 06/30/2026 | 1202418282 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $36,291.31 | 12/31/2025 | Covered Recipient Teaching Hospital Our Lady Of The Lake Rmc | A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB N2 NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Follow | No dispute reported | 06/30/2026 | 1232923928 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $102,712.11 | 12/31/2025 | Covered Recipient Teaching Hospital Our Lady Of The Lake Rmc | A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB N2 NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Follow | No dispute reported | 06/30/2026 | 1232923954 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $36,032.31 | 12/31/2025 | Covered Recipient Teaching Hospital Our Lady Of The Lake Rmc | An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab MK-3475 in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater than | No dispute reported | 06/30/2026 | 1232928269 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $104,184.48 | 12/31/2025 | Covered Recipient Teaching Hospital Our Lady Of The Lake Rmc | An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab MK-3475 in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater than | No dispute reported | 06/30/2026 | 1232928271 |
| Principal investigator 1 | Amgen Inc. | $20,555.00 | 12/24/2025 | Covered Recipient Teaching Hospital Our Lady Of The Lake Rmc | A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305) | No dispute reported | 06/30/2026 | 1246638102 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $3,350.00 | 12/10/2025 | Covered Recipient Teaching Hospital Our Lady Of The Lake Rmc | A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1236000392 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $12,188.42 | 11/19/2025 | Non-covered Recipient Entity Our Lady Of The Lake Rmc | A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome in Erythropoiesis-Stimulating Agent naive Participants who are Non-Transfusion Dependent | No dispute reported | 06/30/2026 | 1235994814 |
| Principal investigator 1 | Amgen Inc. | $500.00 | 10/13/2025 | Covered Recipient Teaching Hospital Our Lady Of The Lake Rmc | A Randomized, Double-Blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared With OPDIVO (Nivolumab) in Subjects With Treatment-Nave Unresectable or Metastatic Melanoma | No dispute reported | 06/30/2026 | 1246638106 |
| Principal investigator 1 | ABBVIE INC. | $1,420.00 | 09/29/2025 | Covered Recipient Teaching Hospital OUR LADY OF THE LAKE RMC | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202418265 |
| Principal investigator 1 | GLOBAL BLOOD THERAPEUTICS, INC. | $1,333.75 | 09/04/2025 | Covered Recipient Teaching Hospital Our Lady Of The Lake Rmc | AN OPENLABEL EXTENSION STUDY TO EVALUATE THE LONGTERM SAFETY OF GBT021601 ADMINISTERED TO PARTICIPANTS WITH SICKLE CELL DISEASE WHO HAVE PARTICIPATED IN A GBT021601 CLINICAL TRIAL | No dispute reported | 06/30/2026 | 1228756224 |
| Principal investigator 1 | ABBVIE INC. | $1,400.00 | 08/19/2025 | Covered Recipient Teaching Hospital OUR LADY OF THE LAKE RMC | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202418262 |
| Principal investigator 1 | ABBVIE INC. | $1,000.00 | 08/05/2025 | Covered Recipient Teaching Hospital OUR LADY OF THE LAKE RMC | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202418258 |
| Principal investigator 1 | ABBVIE INC. | $1,000.00 | 07/31/2025 | Covered Recipient Teaching Hospital OUR LADY OF THE LAKE RMC | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) | No dispute reported | 06/30/2026 | 1202418253 |
| Principal investigator 1 | GLOBAL BLOOD THERAPEUTICS, INC. | $526.00 | 07/31/2025 | Covered Recipient Teaching Hospital Our Lady Of The Lake Rmc | AN OPENLABEL EXTENSION STUDY TO EVALUATE THE LONGTERM SAFETY OF GBT021601 ADMINISTERED TO PARTICIPANTS WITH SICKLE CELL DISEASE WHO HAVE PARTICIPATED IN A GBT021601 CLINICAL TRIAL | No dispute reported | 06/30/2026 | 1228755369 |
| Principal investigator 1 | GLOBAL BLOOD THERAPEUTICS, INC. | $745.00 | 07/31/2025 | Covered Recipient Teaching Hospital Our Lady Of The Lake Rmc | AN OPENLABEL EXTENSION STUDY TO EVALUATE THE LONGTERM SAFETY OF GBT021601 ADMINISTERED TO PARTICIPANTS WITH SICKLE CELL DISEASE WHO HAVE PARTICIPATED IN A GBT021601 CLINICAL TRIAL | No dispute reported | 06/30/2026 | 1228755468 |
| Principal investigator 1 | GLOBAL BLOOD THERAPEUTICS, INC. | $1,060.00 | 07/31/2025 | Covered Recipient Teaching Hospital Our Lady Of The Lake Rmc | AN OPENLABEL EXTENSION STUDY TO EVALUATE THE LONGTERM SAFETY OF GBT021601 ADMINISTERED TO PARTICIPANTS WITH SICKLE CELL DISEASE WHO HAVE PARTICIPATED IN A GBT021601 CLINICAL TRIAL | No dispute reported | 06/30/2026 | 1228757540 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $22,305.00 | 07/25/2025 | Non-covered Recipient Entity OUR LADY OF THE LAKE PHYSICIAN GROUP | A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia | No dispute reported | 06/30/2026 | 1190308544 |
| Principal investigator 1 | Celgene Corporation | $24,356.59 | 06/25/2025 | Covered Recipient Teaching Hospital Our Lady Of The Lake Rmc | A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1222304899 |
| Principal investigator 1 | Amgen Inc. | $2,760.13 | 04/23/2025 | Covered Recipient Teaching Hospital Our Lady Of The Lake Rmc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent Chemoradiation Therapy | No dispute reported | 06/30/2026 | 1246638104 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $158.65 | 04/09/2025 | Covered Recipient Teaching Hospital Our Lady Of The Lake Rmc | A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Locally Advanced or Metastatic NSCLC without Actionable Genomic Alterations (D926NC00001; AVANZAR) | No dispute reported | 06/30/2026 | 1185541772 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,679.39 | 03/25/2025 | Non-covered Recipient Entity Our Lady Of The Lake Rmc | A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING MEZIGDOMIDE (CC-92480), BORTEZOMIB AND DEXAMETHASONE (MEZIVd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): SUCCESSOR-1 | No dispute reported | 06/30/2026 | 1235994812 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $2,265.41 | 03/19/2025 | Non-covered Recipient Entity Our Lady Of The Lake Rmc | A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome in Erythropoiesis-Stimulating Agent naive Participants who are Non-Transfusion Dependent | No dispute reported | 06/30/2026 | 1235994816 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $858.21 | 03/17/2025 | Covered Recipient Teaching Hospital Our Lady Of The Lake Rmc | A PHASE 23 RANDOMIZED MULTICENTER STUDY OF GBT021601 ADMINISTERED ORALLY TO PARTICIPANTS WITH SICKLE CELL DISEASE AND AN OPENLABEL PHARMACOKINETICS STUDY IN PEDIATRIC PARTICIPANTS WITH SICKLE CELL DISEASE | No dispute reported | 06/30/2026 | 1228746805 |
| Principal investigator 1 | Celgene Corporation | $23,214.04 | 03/14/2025 | Covered Recipient Teaching Hospital Our Lady Of The Lake Rmc | A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1222304933 |
| Principal investigator 1 | AstraZeneca UK Limited | $17,131.35 | 03/11/2025 | Covered Recipient Teaching Hospital Our Lady Of The Lake Rmc | An Observational Multi-center Study to Evaluate Real-World Treatment Outcomes of Durvalumab-based Regimens in Hepatobiliary Cancers | No dispute reported | 06/30/2026 | 1185541774 |
| Principal investigator 1 | PFIZER INC. | $10,510.00 | 02/28/2025 | Non-covered Recipient Entity LSU Health Baton RougeNorth Clinic | A PHASE 23 RANDOMIZED MULTICENTER STUDY OF GBT021601 ADMINISTERED ORALLY TO PARTICIPANTS WITH SICKLE CELL DISEASE AND AN OPENLABEL PHARMACOKINETICS STUDY IN PEDIATRIC PARTICIPANTS WITH SICKLE CELL DISEASE | No dispute reported | 06/30/2026 | 1228774827 |
| Principal investigator 1 | Amgen Inc. | $24,605.54 | 02/22/2025 | Covered Recipient Teaching Hospital Our Lady Of The Lake Rmc | A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 193 in Subjects With Methylthioadenosine Phosphorylase (MTAP)-Deleted Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1246638100 |
| Principal investigator 1 | Amgen Inc. | $14,167.73 | 01/27/2025 | Covered Recipient Teaching Hospital Our Lady Of The Lake Rmc | A Noninterventional Biomarker Study on the Molecular Evaluation of Archival Tumor Tissue in Subjects with Advanced or Metastatic Malignancies | No dispute reported | 06/30/2026 | 1246638098 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $19,225.00 | 01/16/2025 | Covered Recipient Teaching Hospital Our Lady Of The Lake Rmc | A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1246660751 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,440.00 | 01/16/2025 | Covered Recipient Teaching Hospital Our Lady Of The Lake Rmc | A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1246660753 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $1,283.70 | 01/15/2025 | Covered Recipient Teaching Hospital Our Lady Of The Lake Rmc | A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato DXd) Versus Investigators Choice of Chemotherapy in Patients who are not Candidates for PD 1/PD L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer | No dispute reported | 06/30/2026 | 1185541770 |